Literature DB >> 28513877

Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Bart A Mulder1, Kevin Damman1, Dirk J Van Veldhuisen1, Isabelle C Van Gelder1, Michiel Rienstra1.   

Abstract

BACKGROUND: Heart rate has been associated with prognosis in patients with heart failure with reduced ejection fraction (HFREF) and sinus rhythm; whether this also holds true in patients with atrial fibrillation (AF) is unknown. HYPOTHESIS: To evaluate cardiac rhythm and baseline heart rate and the influence of outcome in patients with HFREF enrolled in the Cardiac Insufficiency Bisoprolol Study II.
METHODS: In total, 2539 patients were stratified according to their baseline heart rhythm (AF or sinus rhythm) and into quartiles of heart rate (≤70 bpm, 71-78 bpm, 79-90 bpm, and >90 bpm). The primary outcome was all-cause mortality. Mean follow-up was 1.3 years.
RESULTS: Mean age was 61 years, mean left ventricular ejection fraction was 28%, and 80% were male. A total of 521 (21%) patients had AF at baseline. The risk associated with all-cause mortality for each 5 bpm increase in heart rate in patients with sinus rhythm (hazard ratio [HR]: 1.06, 95% confidence interval [CI]: 1.01-1.11, P = 0.012) was significantly different from those with AF (HR: 1.00, 95% CI: 0.94-1.07, P = 0.90, P for interaction = 0.041). The risk associated with higher heart rate in sinus rhythm was primarily attributable to excess risk in the highest quartile (HR: 1.64, 95% CI: 1.18-2.30, P = 0.003). Allocation to bisoprolol did not modify the interaction between heart rate, rhythm and outcome.
CONCLUSIONS: In HFREF patients with AF, a higher heart rate is not associated with increased event rates in contrast to HFREF patients with sinus rhythm.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Atrial Fibrillation; Bisoprolol; Cardiovascular Outcome; Heart Failure; Heart Rate

Mesh:

Substances:

Year:  2017        PMID: 28513877      PMCID: PMC6490317          DOI: 10.1002/clc.22725

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  26 in total

1.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.

Authors:  Ali Vazir; Brian Claggett; Pardeep Jhund; Davide Castagno; Hicham Skali; Salim Yusuf; Karl Swedberg; Christopher B Granger; John J V McMurray; Marc A Pfeffer; Scott D Solomon
Journal:  Eur Heart J       Date:  2014-11-02       Impact factor: 29.983

2.  Lenient versus strict rate control in patients with atrial fibrillation.

Authors:  Isabelle C Van Gelder; Hessel F Groenveld; Harry J G M Crijns; Ype S Tuininga; Jan G P Tijssen; A Marco Alings; Hans L Hillege; Johanna A Bergsma-Kadijk; Jan H Cornel; Otto Kamp; Raymond Tukkie; Hans A Bosker; Dirk J Van Veldhuisen; Maarten P Van den Berg
Journal:  N Engl J Med       Date:  2010-03-15       Impact factor: 91.245

3.  Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality.

Authors:  Kevin Damman; Adriaan A Voors; Hans L Hillege; Gerjan Navis; Philippe Lechat; Dirk J van Veldhuisen; Henry J Dargie
Journal:  Eur J Heart Fail       Date:  2010-08-04       Impact factor: 15.534

4.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

5.  Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study.

Authors:  Vincent E Hagens; Harry J G M Crijns; Dirk J Van Veldhuisen; Maarten P Van Den Berg; Michiel Rienstra; Adelita V Ranchor; Hans A Bosker; Otto Kamp; Jan G P Tijssen; Nic J G M Veeger; Isabelle C Van Gelder
Journal:  Am Heart J       Date:  2005-06       Impact factor: 4.749

6.  Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Otto Kamp; Michiel Rienstra; Hans A Bosker; Nic J G M Veeger; Jan G P Tijssen; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  Heart Rhythm       Date:  2005-01       Impact factor: 6.343

Review 7.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

8.  Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study.

Authors:  Bart A Mulder; Dirk J Van Veldhuisen; Harry J G M Crijns; Jan G P Tijssen; Hans L Hillege; Marco Alings; Michiel Rienstra; Hessel F Groenveld; Maarten P Van den Berg; Isabelle C Van Gelder
Journal:  Eur J Heart Fail       Date:  2013-06-12       Impact factor: 15.534

Review 9.  Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.

Authors:  Michiel Rienstra; Kevin Damman; Bart A Mulder; Isabelle C Van Gelder; John J V McMurray; Dirk J Van Veldhuisen
Journal:  JACC Heart Fail       Date:  2013-02-04       Impact factor: 12.035

10.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.

Authors:  Davide Castagno; Hicham Skali; Madoka Takeuchi; Karl Swedberg; Salim Yusuf; Christopher B Granger; Eric L Michelson; Marc A Pfeffer; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2012-05-15       Impact factor: 24.094

View more
  5 in total

1.  Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Authors:  Bart A Mulder; Kevin Damman; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Clin Cardiol       Date:  2017-05-17       Impact factor: 2.882

2.  Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.

Authors:  Nadia Bouabdallaoui; Eileen O'Meara; Virginie Bernier; Michel Komajda; Karl Swedberg; Luigi Tavazzi; Jeffrey S Borer; Michael Bohm; Ian Ford; Jean-Claude Tardif
Journal:  ESC Heart Fail       Date:  2019-10-08

3.  The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction.

Authors:  Fadel Bahouth; Adi Elias; Itai Ghersin; Emad Khoury; Omer Bar; Haitham Sholy; Johad Khoury; Zaher S Azzam
Journal:  ESC Heart Fail       Date:  2021-11-25

4.  Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial.

Authors:  William T Abraham; Jonathan P Piccini; Christopher Dufton; Ian A Carroll; Jeffrey S Healey; Christopher M O'Connor; Debra Marshall; Ryan Aleong; Dirk J van Veldhuisen; Michiel Rienstra; Stephen B Wilton; Michel White; William H Sauer; Inder S Anand; Sophia P Huebler; Stuart J Connolly; Michael R Bristow
Journal:  Heart Rhythm O2       Date:  2021-11-14

Review 5.  Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology.

Authors:  Domenico D'Amario; Massimiliano Camilli; Stefano Migliaro; Francesco Canonico; Mattia Galli; Alessandra Arcudi; Rocco Antonio Montone; Josip Andjelo Borovac; Filippo Crea; Gianluigi Savarese
Journal:  Curr Cardiol Rep       Date:  2020-08-08       Impact factor: 2.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.